BioSpace News Archive

--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $43.6 Million for Third Quarter 2020-- --Marketing Authorization for ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion Granted in European Union-- --Supplemental New Drug Application (sNDA) Approved by U.S. FDA for ARIKAYCE, Adding Culture Conversion Data Beyond 12 Months to Label-- --Three Key Clinical Trials Expected to Begin by End of 2020: Phase 3 ASPEN Study of Brensocatib in Non-Cystic Fibros

Quarterly net revenues of $132.7 million, representing 44 percent growth versus the third quarter 2019 and 14 percent growth versus the second quarter 2020

Post-hoc, pooled analyses of three Phase 3 trials found HRS-1 patients treated with terlipressin was associated with less RRT up to Day 90 versus placebo

Third Quarter Revenues of $628.3 million, down 3.1% versus Prior Year Period on an As-Reported basis; down 4.1% on a Constant Currency basis

Teleflex Incorporated announced that its Board of Directors declared a quarterly cash dividend of thirty-four cents per share of common stock.

Annovis Bio Inc., a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, announced it resumed treatment of patients in its Phase 2a clinical trial in early AD patients following the suspension of the trial in March 2020 due to COVID-19.

Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, reported financial results for the third quarter ended September 30, 2020, and provided a business update on recent corporate and clinical developments.

Alexion Pharmaceuticals, Inc. announced financial results for the third quarter of 2020. Total revenues in the third quarter were $1,588.7 million, a 26 percent increase compared to the same period in 2019.

Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Company’s third quarter 2020 financial results will be released on Thursday, November 5, 2020.

Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host a conference call and live webcast on Thursday, November 5, 2020, at 8:30 a.m